Pulmatrix Inc (PULM) - Total Liabilities
Based on the latest financial reports, Pulmatrix Inc (PULM) has total liabilities worth $249.00K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Pulmatrix Inc annual equity growth to track the company's year-over-year net asset growth rate.
Pulmatrix Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Pulmatrix Inc's total liabilities have evolved over time, based on quarterly financial data. See Pulmatrix Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Pulmatrix Inc Competitors by Total Liabilities
The table below lists competitors of Pulmatrix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Filtronic
LSE:FTC
|
UK | GBX14.42 Million |
|
GD Culture Group Limited
NASDAQ:GDC
|
USA | $2.63 Trillion |
|
Carmat
PA:ALCAR
|
France | €93.56 Million |
|
Dynasty Gold Corp
V:DYG
|
Canada | CA$542.41K |
|
Solis Minerals Ltd
V:SLMN
|
Canada | CA$505.04K |
|
Clinical Laserthermia Systems AB (publ)
ST:CLS-B
|
Sweden | Skr9.92 Million |
|
Mexican Gold Corp
V:MEX
|
Canada | CA$134.27K |
|
E Media Holdings Ltd
JSE:EMH
|
South Africa | ZAC1.80 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Pulmatrix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pulmatrix Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulmatrix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulmatrix Inc (2012–2024)
The table below shows the annual total liabilities of Pulmatrix Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $996.00K | -93.76% |
| 2023-12-31 | $15.96 Million | +62.16% |
| 2022-12-31 | $9.84 Million | -13.41% |
| 2021-12-31 | $11.37 Million | -24.36% |
| 2020-12-31 | $15.03 Million | -40.07% |
| 2019-12-31 | $25.08 Million | +771.10% |
| 2018-12-31 | $2.88 Million | -50.71% |
| 2017-12-31 | $5.84 Million | -26.08% |
| 2016-12-31 | $7.90 Million | -35.58% |
| 2015-12-31 | $12.27 Million | +1195.35% |
| 2014-12-31 | $947.00K | 0.00% |
| 2013-12-31 | $947.00K | +837.62% |
| 2012-12-31 | $101.00K | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic appli… Read more